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Objective: Between May 1990 and January 1994, 18 patients underwent en 
bloc double-lung transplantation with tracheal anastomosis and bronchial 
arterial revascularization. Because at that time it was already suggested 
that chronic ischemia could be a contributing factor in occurrence of 
obliterative bronchiolitis, the purpose of this study was to evaluate, with a 
follow-up ranging from 22 to 69 months, the midterm effects of bronchial 
arterial revascularization on development of obliterative bronchiolitis. 
Results: Results were assessed according to tracheal healing, functional 
results, rejection, infection, and incidence of obliterative bronchiolitis. 
There were no intraoperative deaths or reexplorations for bleeding related 
to bronchial arterial revascularization, but there were three hospital deaths 
and five late deaths, two of them related to obliterative bronchiolitis. 
According to the criteria previously defined, tracheal healing was assessed 
as grade I, IIa, or IIb in 17 patients and grade I I Ia in only one patient. Early 
angiography (postoperative days 20 to 40) demonstrated a patent graft in 
11 of the 14 patients in whom follow-up information was obtained. Ten 
patients are currently alive with a 43-month mean follow-up. Among the 15 
patients urviving more than 1 year, functional results have been excellent 
except in five in whom obliterative bronchiolitis has developed and who had 
an early or late graft thrombosis. Furthermore, those patients had a 
significantly higher incidence of late acute rejection (p < 0.02), cytomega- 
lovirus disease (p < 0.006), and bronchitis episodes (/1 < 0.0008) than 
patients free from obliterative bronchiolitis. Conclusion: We conclude that 
besides its immediate beneficial effect on tracheal healing, long-lasting 
revascularization was, at least in this small series, associated with an 
absence of obliterative bronchiolitis, thus suggesting but not yet proving the 
possible role of chronic ischemia in this multifactorial disease. (J Thorac 
Cardiovasc Surg 1996;112:1292-300) 
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T he advantages and feasibility of restoring the bronchial arterial circulation in lung transplanta- 
tion to improve airway healing was demonstrated as 
early as 1950 by M6tras 1 and was confirmed in 
animal experiments in 1970 by Mills, Boyd, and 
Gheranpong. 2 In 1990, Schreinemakers and associ- 
ates 3 pointed out, in a both provocative and good 
sense aphorism, that "it makes as much sense to 
transplant lungs without bronchial arteries as to 
transplant hearts without coronary arteries." Coo- 
per had concluded this discussion hoping that "res- 
toration of bronchial circulation could become a 
routine part of single-lung, double-lung, and heart- 
lung transplantation. ''3 In fact, in the early days of 
clinical lung transplantation, the significant morbid- 
ity and mortality related to airway ischemia 4 con- 
firmed that the lack of blood supply was harmful and 
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responsible for these dreadful complications. How- 
ever, bilateral ung transplantation remained a nec- 
essary therapeutic option for patients with septic 
end-stage lung diseases; because airway complica- 
tions were less likely to occur in heart-lung trans- 
plantation, this option was chosen when a bilateral 
transplant was needed. Nevertheless, since 1986, 
because of the shortage of heart-lung block donors 
and the need to use the heart alone for another 
recipient, the surgical technique of double-lung 
transplantation (DLT) has evolved. Many tech- 
niques were developed to prevent ischemia, 5 such as 
wrapping the airway anastomosis with omental and 
mediastinal flaps. More recently, some authors in- 
troduced alternative techniques uch as sequential 
DLT with bronchial anastomosis, 6 and for the same 
reason, other groups initiated single-lung transplan- 
tation with contralateral pneumonectomy. 7 At last, 
improvement in organ preservation and techniques 
for bronchial anastomosis, as well as a better man- 
agement of immunosuppression a d rejection sur- 
veillance, have considerably reduced the prevalence 
of airway complications. 8 
Despite a dramatic improvement in the immedi- 
ate results of lung transplantation, however, the 
occurrence of obliterative bronchiolitis (OB) re- 
mains the most feared complication. It represents, 
at midterm and long-term follow-up, an obvious 
failure of lung transplantation. 9 Alloimmune re- 
sponses, rejection, and infection episodes have been 
demonstrated to be of fundamental importance in 
the pathogenesis of OB, 1° but the devascularization 
and consequently the chronic ischemia of the tra- 
cheobronchial tree could be a nonnegligible contrib- 
uting factor. For this reason, after anatomic and 
angiographic studies of the tracheobronchial arterial 
blood supply, 3' 11, 12 we developed in 1990 a simpl e 
technique of bronchial arterial revascularization for 
en bloc DLT with tracheal anastomosis. Our first 
results in eight patients with a mean follow-up of 11 
months were reported in 1992.13 But this too short 
follow-up did not allow us to assess whether bron- 
chial arterial revascularization could have some 
beneficial impact in decreasing the incidence of OB. 
The purpose of this study is thus to evaluate, with a 
longer follow-up, the possible effect of revascular- 
ization on OB occurrence. 
Patients and methods 
Between May 1990 and January 1994, 18 patients 
underwent en bloc DLT with tracheal anastomosis and 
bronchial arterial revascularization in the Department of 
Thoracic Surgery at Xavier Arnozan Hospital. There were 
13 male and five female patients with a mean age of 
43.6 _+ 11.9 years (range 16 to 63 years). Indications for 
DLT were chronic obstructive pulmonary disease in nine 
patients, of whom two had an c~l-antitrypsin deficiency, 
cystic fibrosis in one, and pulmonary fibrosis in eight 
patients, for whom DLT was preferred because of recur- 
rent infectious complications. All these patients, depen- 
dent on supplemental oxygen were in New York Heart 
Association functional class III (38.9%) or IV (61.1%). 
All the donor organs but four were from local procure- 
ment, and for all the recipients but one, the graft was 
ABO identical. 
Operative technique for donor lung harvesting, organ 
preparation, recipient operation, and organ implantation, 
as well as the revascularization procedure, have been 
previously described, lz' 13 The main steps of the technique 
are designed to preserve the right intercostobronchial 
artery or a common bronchial arterial trunk supplying the 
right and left main bronchi, as well as the periesophageal 
and subcarinal network. Consequently, so that these col- 
lateral networks upplying both bronchi will not be dis- 
rupted, the orifice of the right intercostobronchial artery is 
not mobilized as a pedicle, but left in place in the posterior 
mediastinum. Thus the procedure for revascularization 
used a saphenous vein graft interposed between the 
orifices of the bronchial arteries and the recipient's as- 
cending aorta. Tightness and runoff of the distal anasto- 
mosis can be checked before implantation of the double- 
lung block by flushing heparinized saline solution into the 
venous graft. 
Standard immunosuppression consisted of cyclospo- 
rine, steroids, azathioprine, and antilymphocyte antibody. 
Cyclosporine was given as a continuous infusion (3 mg/kg) 
at the beginning of the operation, followed by enteral 
administration. The dose was adjusted to obtain a blood 
level between 150 and 250 ng/ml. Methylprednisolone was 
administered intravenously (500 rag) during the transplan- 
tation and followed by oral prednisolone (1 mg/kg per 
day) quickly tapered to 0.2 mg/kg per day: A 5-day course 
of intravenous prostacyclin (Flolan, Burrows Wellcome 
Co., Research Triangle Park, N.C.) was given in seven of 
18 patients. All the patients but three (cytomegalovirus 
seronegative r ceiving a seronegative graft) had 8 to 21 
days of prophylaxis with ganciclovir (Cimevan, Roche 
Laboratories, Nutley, N.J.). All the patients had the same 
antibacterial prophylaxis with imipenem and ciproflox- 
acine for 5 days, and trimethoprin sulfameth0xazole was 
given until the fifteenth postoperative day to prevent 
Pneumocystis carinii infection. 
A flexible fiberoptic bronch0scope was used almost 
every day during the first week for bronchial aspirations 
and analyses and then routinely twice a week or when 
dictated by clinical parameters. Bronchoscopy with pho- 
tographs was performed between days 15 and 20 to assess 
tracheal healing according to the classification previously 
described. 14
Baseline venous graft angiography was performed be- 
tween the third and fourth weeks after the transplanta- 
tion. Long-term patency was also assessed by angiography 
in seven living patients in whom the graft was initially 
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Table I. Early comparative assessment of tracheal 
healing and venous graft patency 
Venous graft baseline 
Tracheal healing angiography 
Patients Patent 
Grade No. % No. of grafts No. % 
I 7 38.9 5 5 100 
IIa 7 38.9 6 3 50 
IIb 3 16.6 2 2 100 
III 1 5.6 1 1 i00 
Total 18 100 14 1I 78.6 
patent or not evaluated in the early posttransplantation 
period. 
The pulmonary functional status was evaluated by the 
usual parameters, which included forced vital capacity 
(FVC), forced expiratory volume in 1 second (FEV1) , 
forced expiratory flow rate between 25% and 75% of the 
forced vital capacity (FEFR25/75), and arterial oxygen 
tension (Pao2) and carbon dioxide tension (Pac%) in 
millimeters of mercury. 
For purposes of this review, pneumonia was defined as 
associating clinical symptoms, radiographic findings, and 
isolation of the pathogen i  the lung, whereas episodes of 
bronchitis were defined as clinical symptoms with isolation 
of the pathogen in the bronchial tree, without radio- 
graphic abnormalities. With regard to cytomegalovirus 
(CMV), biologic infection was defined as a positive vire- 
mia Or the discovery Of the virus in the bronchoalveolar 
lavage without CliniCal symptoms, and CMV disease was 
defined as the association of clinical symptoms, radio- 
graphic abnormalities, and the presence of the virus in a 
tissue. Rejection was diagnosed on the basis of transbron- 
chial lung biopsy histology by means of the International 15 Classification or on clinical and paraclinical findings 
with a good response to specific treatment. As recom- 
mended in the literature, we have opted for the Interna- 
tional Classification of Bronchiolitis Obliterans Syn- 
drome.16 
Infection was treated with specific antimicrobial gents. 
Acute rejection was treated with a 3-day bolus methyl- 
prednisol0ne course (1 gm dose) or with OKT3 for 10 
days in the event of any resistant or persistent rejection. 
CMV biologic infections or diseases were treated with a 
15-day course of ganciclovir. All the patients with OB had 
an increase in immunosuppression at the very least. 
With regard to statistical analysis, data are expressed as 
mean plus or minus 1 standard eviation. Actuarial sur- 
vival was calculated with the Kaplan-Meier method. 
Paired t test was used to evaluate the differences over time 
within all patients for the respiratory parameters. Signif- 
icance was sought between the two groups of patients with 
and without OB with the use of ~ test for nonparametric 
data and Student's t test for continuous data. Statistical 
significance was accepted at the 95% confidence l vel, p < 
0.05. 
Results 
Early events. Three patients required reexplora- 
tion for early bleeding related to previous pleural 
adhesions, but there was no bleeding related to 
bronchial arterial revascularization. There was no 
intraoperative death, and all patients but two were 
extubated in a mean of 1.9 days (range 12 hours to 
4 days). 
Tracheal healing. All 18 patients had bronchos- 
copy to assess tracheal healing. Staging results are 
shown in Table I. According to our classification, 14
17 patients (94.4%) had grade I or II healing, and no 
late stenosis was observed in patients discharged 
from the hospital. Grade I I Ia was assessed in only 
one patient, without subsequent complication. 
Therefore no early tracheal dehiscence was detected 
in these patients. 
Hospital mortality. There were three hospital 
deaths (16.6%). Among the patients who died were 
the two who could not be weaned from the ventila- 
tor. The first one, a 56-year-old man with emphy- 
sema and alveolar proteinosis, ventilator-dependent 
before transplantation, died on postoperative day 16 
of multiorgan failure. However, there was no graft 
dysfunction and tracheal healing was excellent. The 
second patient, a 63-year-old woman, died on post- 
operative day 51 of cataclysmic hemoptysis. On 
postoperative day 15 tracheal healing was classed as 
grade I, but bronchial necrosis subsequently devel- 
oped with severe infection (Pseudomonas eruginosa 
and Aspergillus fumigatus) and severe steroid-resis- 
tant acute rejection treated with OKT3. She soon 
required tracheotomy and stenting of the main 
bronchus for severe distal malacia. The hemorrhage 
was probably due to vascular erosion and rupture in 
relation with the Gianturco stent. This death was 
obviously related to an airway complication, as 
defined by Date and associates, s but the respective 
responsibility of necrotizing infection and of a prob- 
able ischemia, despite adequate tracheal healing, 
remained questionable. The third patient, a 35-year- 
old man with paraquat poisoning, had an uneventful 
immediate postoperative course, but he died 35 days 
later of massive intestinal hemorrhage. 
Early venous graft patency. Only three of the 14 
patients undergoing early baseline angiography had 
a graft occlusion at the time of the angiogram but 
nevertheless had grade I Ia tracheal healing (Table 
I). The 11 other patients had a patent venous graft 
with a good runoff in the bronchial circulation. 
Therefore the early patency rate in these 14 patients 
was 78.6%. 
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Morbidity. Follow-up of the 15 patients dis- 
charged from the hospital ranged from 22 to 69 
months. The main events in these patients are 
shown in Table II. Four patients did not have any 
episode of rejection; almost all episodes of rejection 
were successfully treated by methylprednisolone 
pulses except in two patients who required OKT3. 
Recipient and donor were not matched for the 
CMV. Thirteen patients were seropositive before 
transplantation and received a seropositive (n = 6) 
or a seronegative (n = 7) graft. Five recipients were 
seronegative and four of them received a seronega- 
tive donor block. Active CMV diseases have devel- 
oped in half of the patients. The site of infection was 
pulmonary in eight cases, gastrointestinal in two, 
and ocular in one. The most frequent complications 
were episodes of bronchitis or pneumonia. The 
causal agent was bacteria, a virus other than CMV, 
or fungi. A pleuropulmonary tuberculosis developed 
4 months after transplantation i one patient and 
responded well to drugs. 
Late deaths and actuarial survival. Five patients 
had died by the last date of follow-up, at a mean 
delay of 570 days (range 324 to 1493 days). Causes 
of death were scleroderma fibrosis relapse in one 
patient, sepsis and end-stage renal failure in two 
others, and OB in two patients. Consequently, the 
actuarial patient survival including hospital mortal- 
ity was, at 1, 2, and 5 years, 77.8% _+ 0.9%, 72.2% + 
1.5%, and 46.9% _+ 1.3%, respectively. 
Functional results. In the 15 surviving patients, 
pulmonary function parameters improved dramati- 
cally as early as 1 month after the transplantation 
(Fig. 1). FVC remained stable over time between 
70% and 90% of predicted values. Of the two other 
parameters, FEFR25/75 was the first to decrease, just 
before FEV~. These alterations were due to OB 
occurrence. But despite FEFR and FEV 1 decrease, 
arterial blood gas analysis remained within normal 
limits, with a mean Pao2 over 75 mm Hg and a 
normal Paco 2 (Fig. 2). 
OB incidence. Of the 15 patients with a follow-up 
ranging from 22 to 69 months (mean 43 months), 
five patients (33%) have had clinical and functional 
features of OB in a mean interval of 19.2 _+ 9 
months. One patient had stage 3a OB and four had 
stage 3b. The histologic diagnosis of OB was proved 
by surgical biopsy in two patients, transbr0nchial 
biopsies in one, and autopsy in another one. We 
failed to prove OB in the last patient who had only 
the clinical and functional features. The treatment 
of OB in all five patients consisted of augmentation 
Table II. Number of early and late acute rejections, 
CMV infections and diseases, and other infectious 
episodes 
Event No. per patient 
Acute rejection (<3 mo) 1 -+ 0.97 
Acute rejection (>3 mo) 0.50 -+ 0.6 
CMV infection 1.28 -- 1.18 
CMV disease 0.78 _+ 1.06 
Bronchitis 2.8 _+ 2.4 
Pneumonia 1.3 _+ 1.08 
Data are mean _+ standard eviation. CMV, Qrtomegalovirus. 
of immunosuppression. Of these, two died. One 
patient recovered and now lives a nearly normal ife. 
Another one requires supplemental oxygen, is not 
ambulatory, and is waiting for a second transplant. 
The last patient underwent retransplantation 26 
months ago and is currently well. In none of these 
patients we did find any relationship of OB with 
human leukocyte antigen (HLA), except that all 
patients with OB had two mismatches on the HLA 
locus A and all but one also had two mismatches On 
HLA locus DR. 17 
Because we hoped that bronchial revasculariza- 
tion could help to prevent OB, the variables listed in 
Table III were compared between the i0 patients 
free from OB (group 1) and the five patients with 
OB (group 2). With a mean f011ow-up of 34.5 
months in group 1 versus 47.2 months in group 2, 
there was no statistically significant difference 
among the following seven variables: recipient and 
donor age, donor stay in the intensive care unit, Cold 
ischemic time, bypass time, duration of mechanical 
ventilation, and incidence of early acute rejection. In 
addition, there was no difference between the two 
groups for HLA matching. With regard to late acute 
rejection, CMV disease, bronchitis, and total infec- 
tion episodes, however, there was a striking and 
highly significant difference between the two groups. 
These events were considerably less prevalent in 
patients free from OB. Moreover, the late graft 
patency associated with long,lasting bronchial revas- 
cularization was 71.4% in group 1 and 0 in group 2. 
Consequently, despite the small number of patients 
in this series, and without asserting any connection 
between cause and effect, the relation between graft 
patency, OB incidence, and late rejection and infec- 
tion episodes can only be pointed out. However, 
statistical analysis of bronchial arterial revascular- 
ization is missing, because this report is a retrospec- 
tive study, and because all the data on the grafts 
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Fig. 1. Pulmonary function parameters over time. The parameters studied were FVC (El), FEV 1 (O), and 
FEFR25/75 (A) expressed as percentage of the predicted value. Each point represents he mean value _+ 
standard error of the mean. Parameters are given before transplantation, at 1, 3, and 6 months, and then 
every 6 months. Figures represent the number of patients evaluated at each time. *p < 0.0001: comparison 
between the parameters (FEV 1 and FEFR25/75) before transplantation a d at 1, 6, and 12 months after 
transplantation). **p < 0.05: comparison between FVC before transplantation a d after 1 month. 
were not available. Some patients had an early 
patent graft, but died without OB and without a late 
graft evaluation. Nevertheless, all the patients with 
OB had graft thrombosis either early or late. 
Discuss ion 
To date, for most of the authors, indications for 
en bloc DLT remain questionable because the 
need for airway revascularization is controver- 
sial. 18 For that reason and because of the atten- 
dant complexity of bronchial arterial revascular- 
ization, this technique has not been widely 
adopted by other transplant groups. When bilat- 
eral lung transplantation is needed, most groups 
performed DLT with distal and telescoping bron- 
chial anastomosis, equential DLT, and pharma- 
cologic agents. 19 A recent report by Date and 
associates* on a large series of single-lung and 
double-lung transplants with bronchial anastomo- 
sis demonstrated that the prevalence of airway 
complications was reduced by the conjunction of 
many factors. However, when tracheal anastomo- 
sis is performed, restoration of tracheobronchial 
blood supply is mandatory. By comparison with 
the early reports on airway complications after 
DLT with tracheal anastomosis, 4 our incidence of 
airway complication is 5.5% (1/18 patients), and 
there was neither early dehiscence nor late stric- 
ture in the surviving patients. In addition, except 
for the one death related to airway complications, 
no other early or late death could be attributable 
to the technique itself. With regard to bronchial 
arterial revascularization, some groups 2°-22 using 
the internal thoracic artery maintain that bron- 
chial revascularization remains useful for lung 
transplantation. The excellent results reported by 
Daly and associates 2° for single-lung and by Pet- 
tersson and colleagues al for en bloc DLT with 
tracheal anastomosis have proved that associated 
revascularization was a well-founded and sound 
policy, at least for the immediate aim of providing a 
satisfactory bronchial or tracheal healing. But what- 
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Fig. 2. Evolution of arterial blood gases over time. The parameters studied were Pao 2 (11) and Paco 2 (@), 
expressed in millimeters of mercury. Each point represents he mean value _+ standard error of the mean. 
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Table III. Comparison of variables between patients free from OB (group 1, n = 10) and with OB (group 2, 
n= 5) 
Group 1 Group 2 
Variable n = 10 n = 5 p Value 
Recipient age (yr) 46.53 ± 11.27 36 _+ 11.1 0.09 NS 
Donor age (yr) 25.84 _+ 6.88 25 ± 8.37 0.8 NS 
Donor ICU stay (hr) 25.88 _+ 10.9 37.6 _+ 20.5 0.13 NS 
Cold ischemia (min) 253.07 ± 51.18 243.6 _+ 28.0 0.7 NS 
Bypass time (min) 202.3 ± 43.76 217.02 _+ 48.5 0.5 NS 
Mechanical ventilation (day) 2.04 ± 1.06 1.60 _+ 0.89 0.4 NS 
Early acute rejection 1 ± 1 1 _+ 1 0.6 NS 
Mean follow-up (mo) 34.5 47.2 
Late graft patency (%) 71.4 0 
Late acute rejection 0.31 + 0.48 1.31 _+ 0.95 0.02 
CMV disease 0.38 ± 0.65 1.8 _+ 1.3 0.006 
Bronchitis 1.69 ± 0.95 5.8 _+ 2.49 0.0008 
Total infection episodes 4.54 _+ 2.44 10.4 _+ 5.13 0.004 
017, Obliterative bronchiolitis; ICU, intensive care unit; CMV,, cytomegalovirus; NS, not significant. 
ever the technique of DLT used, functional results 
of bilateral transplantation are obviously betterY 
With regard to the choice of the conduit used for 
revascularization, the saphenous vein graft is easy 
and safe to use. It is likely to provide an excellent 
immediate blood supply, because the fish-mouth 
shaped distal anastomosis of the graft allows it to 
cover as many orifices of bronchial arteries as 
needed and thus ensures an optimal revasculariza- 
tion. But the internal thoracic artery, as advocated 
by Yacoub, Daly, and Pettersson, is well known to 
provide a more lasting blood supply than a venous 
graft. There is a better size concordance between 
thoracic artery and bronchial arterial runoff. More- 
over, the physiologic ability of the arterial conduit o 
respond to changes in flow requirements with ap- 
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propriate vasodilation and constriction explains its 
capability to remain patent when anastomosed to
small vessels. In the same situation, avenous graft is 
more likely to be thrombosed. Consequently, the 
internal thoracic artery should certainly be consid- 
ered as the conduit of choice for this purpose. When 
considering the only immediate aim of airway heal- 
ing, however, an early bronchial arterial revascular- 
ization success lasting 2 or 3 weeks appears to be 
sufficient for providing excellent airway healing. 
With regard to long-term functional results, the 
effects of long-lasting revascularization remain to be 
explored. It is unlikely that revascularization could 
have an impact on alloimmune responses, because 
transplantation f vascularized organs such as kid- 
ney, liver, or heart does not prevent chronic rejec- 
tion. However, after lung transplantation, lung phys- 
iology is greatly impaired. Several factors such as 
bronchial denervation and devascularization, as well 
as reperfusion injury, may have a role in the modi- 
fication of mucociliary clearance and the structure 
and function of the bronchial epithelium. 24-26 Some 
of these factors could recover partially during the 
late postoperative period. 27 However, all these fac- 
tors, as well as immunologic reactions and infec- 
tions, can be involved in the pathogenesis of OB. 
Because these possible pathogenetic factors cannot 
be identified and checked separately in human 
transplantation, it was attractive to assess whether 
or not long-lasting revascularization could have a 
beneficial impact on lung function. It is certainly 
speculative, but also quite possible, that late patent 
bronchial arterial revascularization could partici- 
pate in restoring physiologic conditions such as 
bronchial epithelium near to normal, with improved 
mucosal trophicity and mucociliary function. Main- 
tenance of these functions could contribute to host 
defense against infection. 25 
OB currently remains the main event limiting the 
long-term success of lung transplantation. Our over- 
all OB incidence of 33% is not different from those 
reported in other publications 1°but has to be cor- 
related with a 43-month mean follow-up. The hy- 
pothesis that long-lasting bronchial arterial revascu- 
larization could contribute to a decrease in OB 
occurrence follows from our findings in a limited 
series, with incomplete data, because the best way to 
survey graft patency through a noninvasive tech- 
nique remains to be defined. Thus our hypothesis 
obviously more a suggestion than a certainty. How- 
ever, because there was, until now, no satisfactory 
answer to an efficient OB prevention, and because it
also has not been proved that chronic ischemia, 
despite the mechanisms of collateral blood supply, 
was harmless and without side effects, it appeared to 
us that this field of clinical research was worth 
exploring. Finally, the definitive answer as to 
whether long-lasting revascularization could be a 
contributing factor of some importance can only be 
confirmed or invalidated by a larger clinical experi- 
ence and a truly longer follow-up. This conclusion 
could emerge from the some groups using the 
long-lasting patent internal thoracic artery for bron- 
chial arterial revascularization. 
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Discuss ion 
Dr. Shaf Keshavjee (Toronto, Ontario, Canada). The 
University of Bordeaux group are to be credited for the 
development of this truly simplified technique of bron- 
chial arterial revascularization in which a saphenous vein 
graft is used and the distal anastomosis is performed on 
the back table. Bronchial arterial revascularization ad- 
dresses two issues, the first being ischemia of the airway 
and the second being OB. Like most other transplant 
programs, we have found that airway ischemia is not as 
large a problem as it was in the past. For example, over the 
past 4 years or so in Toronto in the last 137 transplants, 
with 262 telescoped, nonrevascularized anastomoses "at 
risk," we have had eight patients (or a 3% incidence of 
stricture) requiring adilatation and one patient (or a 0.4% 
incidence of stricture) requiring a stent. This improve- 
ment in airway healing is likely attributable to multiple 
factors including anastomotic technique and lung preser- 
vation. Thus, although the problem is not as large as it 
used to be, there still is room for improvement. 
The major issue, then, is the role of bronchial arterial 
revascularization n the prevention of OB. In this series of 
18 patients, the authors report an incidence of OB of 28%, 
which is not different from results from centers not 
performing bronchial arterial revascularization. I terest- 
ingly, however, all patients with OB had an occluded vein 
graft. My question is this: Which is the horse and which is 
the cart? Did the vein graft occlusion lead to OB or vice 
versa? 
Finally, as the authors have indicated, OB is likely a 
multifactorial phenomenon. The situation of chronic rel- 
ative ischemia wherein the transplanted lung bronchus is 
fed by pulmonary arterial blood, which is low in saturation 
and has a low perfusion pressure, may indeed be a 
significant contributing factor. However, I think that the 
only way we are going to be able to conclusively prove it is 
by performing a study of unilateral bronchial arterial 
revascularization in bilateral ung transplant recipients. 
Dr. Baudet, I would like to ask your opinion with respect 
to that sort of a study, in which case each patient would 
serve as his own control. 
Dr. Baudet. Thank you for your comments. To answer 
your first question, despite our findings that OB did not 
develop in patients with a long-term patent venous graft, 
it could be asserted that rejection and infection associated 
with OB occurrence could impair the distal bronchial 
arterial bed, reduce the runoff, and thus might be respon- 
sible for graft occlusion. But our data were given just as 
findings suggesting a hypothesis, rather than being an 
assertion. If the 28% OB incidence in our series is not 
different from that of centers not performing bronchial 
arterial revascularization, it has to be correlated with a 
longer follow-up than in the other series. The longer the 
follow-up, the higher the OB incidence, which is more 
than 28% in reports with a follow-up longer than 5 years. 
With regard to your suggestion of one-lung revasculariza- 
tion in sequential bilateral lung transplantation so that the 
patient would act as his or her own control, this aim could 
be achieved by revascularization f the left lung with the 
internal thoracic artery, as performed by Yacoub, or of the 
right lung by direct anastomosis of the right intercosto- 
bronchial artery into the aorta. This may be a partial 
answer for the pathogenesis of this multifactorial disease. 
Dr. Gosta Pettersson (Copenhagen, Denmark). We all 
recognize the pioneering work of the Bordeaux group in 
relation to direct bronchial arterial revascularization in 
lung transplantation. I  Copenhagen we were convinced 
from the beginning that the beneficial effect of successful 
revascularization went beyond healing of the airway anas- 
tomosis; therefore we used the internal thoracic artery, as 
proposed by Yacoub, as a conduit. In Copenhagen we 
have performed, 53 DLTs, eight single-lung transplanta- 
tions, and nine heart-lung transplantations with bronchial 
arterial revascularization. The 1- and 2-year survival of the 
DLTs is 82%. We have a 94% early patency of the 
bronchial arterial revascularization, and we have now 
reexamined 20 patients with primarily patent revascular- 
ization after 2 years. All 20 have patent bronchial arterial 
revascularization. Vascularity has even improved uring 
that period. 
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Unfortunately, I am not able to confirm your observa- 
tion that the incidence of OB syndrome should be excep- 
tionally low with functioning revascularization. We have a 
1-, 2-, and 3-year incidence of OB syndrome of 85%, 82%, 
and 67%, respectively. We have not yet correlated our OB 
syndrome results with the arteriographic findings. 
I would like to ask you if you have done any grading of 
the success you have achieved with your revasculariza- 
tion? I would like you once again to come back with a 
suggestion about design of a study to confirm or exclude 
that revascularization makes a difference. I am in doubt 
about the suggestion of doing revascularization one 
side and not the other. By chance we have had hemilat- 
erally successful revascularization, and we have seen 
severe OB syndrome in both lungs for one of those 
patients. OB syndrome, per se, seems to be associated 
with increased vascularity rather than the opposite. That is 
a comment addressed to one of the previous questions. 
Dr. Baudet. Thank you, Dr. Pettersson, for your com- 
ments. Your technique of revascularization using the 
internal thoracic artery, as proposed by Yacoub and also 
performed by Daly, is certainly the best way to achieve 
long-lasting revascularization. That is already confirmed 
by your experience. But your 2-year incidence of OB is 
somewhat disappointing. However, since this 45% inci- 
dence includes patients with primarily failed revascular- 
ization, these results, as you mentioned, have to be 
correlated with the results of arteriographic findings. 
To answer your question, we have not done any revas- 
cularization grading but only a tracheal healing grading. 
However, revascularization using a venous graft, able to 
cover as many orifices of bronchial arteries as needed, is 
likely to provide a more complete bilateral revasculariza- 
tion, as demonstrated by our early and late angiographic 
studies. Nevertheless, because long-lasting revasculariza- 
tion is more frequently achieved when using the internal 
thoracic artery, the groups like yours, using this conduit, 
will be more able to answer this question. The best way to 
survey graft patency, whatever the conduit used, remains 
to be defined through noninvasive methods. 
Dr. Joel D. Cooper (St. Louis, Mo.). There is no 
question that if you choose to do this en bloc operation, 
your revascularization technique is probably extremely 
important in reducing airway complications. However, my 
question is, why would you want to do this? If you consider 
your series overall, nothing in this series has accomplished 
anything better than has been reported by standard meth- 
ods without revascularization. There is no lower hospital 
mortality rate; there is no reduction in overall incidence of 
OB; there is no reduction in deaths or complications from 
airway anastomoses. In the St. Louis Registry, which 
contains more than 4000 cases from around the world, the 
incidence of death from airway complications i 1% or 
less. Your technique does not reduce the incidence of OB 
or airway complications or improve either hospital sur- 
vival or long-term survival. I would thus ask, as someone 
who has had the opportunity of performing both types of 
operations, why would you want to do an en bloc DLT, 
which is complicated and requires prolonged cardiopul- 
monary bypass, when the world experience at many cen- 
ters has accomplished the same overall goals using a 
simpler type of transplant? 
Dr. Baudet. Thank you, Dr. Cooper, for your comments 
and questions. The first aim of bronchial arterial revascu- 
larization was to improve airway healing because, at that 
time, the sequential technique was not yet used for 
bilateral ung transplantation; thus we have chosen to 
perform DLT with tracheal anastomosis. 
In our opinion, for patients needing bilateral lung 
transplantation, the en bloc technique offered the advan- 
tages of reducing the duration of the operation and the 
donor organ ischemia, which can be very long for the 
second lung in sequential DLT. Because of a close collab- 
oration between the Departments of Thoracic Surgery 
and of Cardiovascular Surgery, the en bloc technique, 
despite requiring cardiopulmonary b pass, which is in fact 
a very simple procedure, never appeared to be compli- 
cated or sophisticated or likely to induce short-term 
complications. The aim of our technique was to achieve a
safe tracheal healing and, by this way, to reduce hospital 
mortality caused by airway dehiscence. In fact, in our 
series, there was no operative mortality, and the three 
hospital deaths were due to causes unrelated to tracheal 
complications or failed revascularization. With regard to 
late deaths, only two were due to OB, the three others 
being unrelated to the technique itself. Consequently, 
there were no early or late deaths attributable to tracheal 
complications. Concerning this point, in the 1996 St. Louis 
Registry, there was a 5% incidence of early deaths result- 
ing from airway dehiscence, but long-term airway compli- 
cations such as stricture or the need for stenting are not 
clearly reported. Finally, the 5% early and the 29% late 
death rates owing to OB/rejection were not correlated to 
the length of follow-up. Our 28% OB incidence was 
observed with a 43-month mean follow-up, ranging from 
22 to 69 months. In the literature, with a such long 
follow-up, the current incidence of OB has been reported 
by the Stanford group to be 36% within the first 3 years, 
with an overall prevalence of 58% after heart-lung and 
51% after lung transplantation. 
I agree that the number of patients in our study is 
relatively small, and that any retrospective study can 
appear to be incomplete. However, since nobody, up to 
now, gave a satisfactory answer to OB prevention, it 
appeared to us that, in this multifactorial disease, the role 
of chronic lung and airway ischemia had to be explored. It 
is already obvious that improvement of mucosal trophicity 
and mucociliary clearance could play an indirect beneficial 
role. I hope that the final answer for this hypothesis can be 
given, for patients with a truly long follow-up, by the 
groups using for revascularization the long-lasting patent 
internal thoracic artery. 
